Organon & Co. (OGN)
Health Care6 articles
Price chart
Why is OGN moving today?
0.0%OGN is 0.0% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 2 days ago
Organon & Co. (OGN) overview
Organon is a women’s-health-focused pharmaceutical company spun off from Merck.
OGN is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Organon & Co. trades on the NYSE under the ticker symbol OGN. The most recent market data puts the share price at about $13.76. That is up 0.00% on the session. At that price the company is worth roughly $3.61B.
Over the past 52 weeks, OGN has traded between $5.69 and $13.83. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 17.6. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. OGN also pays a dividend. It yields around 0.58% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 2 days ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch OGN
OGN is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each OGN story as it breaks, and tags it bullish, bearish or neutral.
What moves OGN
- Earnings. OGN reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from OGN.
- Sector news. Health Care stocks often move together, so a rival's news can move OGN too.
Market Mood
Latest OGN news
Organon & Co (OGN) Stock Reaches 52-Week High of 13.73 USD
Organon & Co (OGN) stock has reached a 52-week high of 13.73 USD. This milestone reflects investor confidence and could signal positive market trends for the company. The stock's performance may influence perceptions of the firm as a viable investment option. For investors, this achievement suggests potential upward momentum in the stock price.
Read More: Organon & Co (OGN) Stock Reaches 52-Week High of 13.73 USD
InvestingPro's Fair Value Indicates Organon 69% Gain Potential
InvestingPro's Fair Value model suggests that Organon (OGN) has a potential upside of 69%. This assessment is based on the company's current valuation relative to its estimated fair value. The findings highlight potential growth opportunities for investors. The model incorporates fundamental metrics and market trends that may influence Organon's stock performance in the near term. Understanding these figures is crucial for investors looking to make informed decisions regarding Organon.
Read More: InvestingPro's Fair Value Indicates Organon 69% Gain Potential
Sun Pharmaceuticals (SUN) Acquires Organon & Co for $11.75 Billion
Sun Pharmaceuticals (SUN) announced an agreement to acquire Organon & Co for $11.75 billion, marking the largest overseas acquisition by an Indian company in nearly 20 years. This deal is part of a broader trend, with 162 Indian companies investing over $18 billion in outbound acquisitions in 2025, reflecting a 34% year-over-year increase. Notable acquisitions include Tata Motors' $4.4 billion purchase and IT firm Coforge's $2.35 billion acquisition. Analysts suggest that Indian firms are increasingly seeking overseas assets for strategic rather than merely symbolic reasons.
Read More: Sun Pharmaceuticals (SUN) Acquires Organon & Co for $11.75 Billion
Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash
Sun Pharmaceutical Industries (SUN) announced its acquisition of Organon & Co for $11.75 billion, valuing the U.S. firm at $14 per share including debt. This deal will position Sun Pharma among the top 25 global pharmaceutical companies, enhancing its revenue from $12.4 billion. The acquisition is expected to increase Sun Pharma's innovative medicine segment contribution to 27% from 20% in the financial year ending March 2025. Organon's portfolio supports Sun Pharma's strategy to grow its Innovative Medicines business, which includes dermatology and oncology products.
Read More: Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash
Sun Pharma (SUN) Acquires Organon for $11.75 Billion
Sun Pharma (SUN) has announced its acquisition of U.S. healthcare firm Organon for $11.75 billion. This deal marks a significant expansion for Sun Pharma, aiming to strengthen its position in the global pharmaceutical market. The acquisition could impact market dynamics as it reflects ongoing consolidation in the healthcare sector. Investors will be monitoring how this transaction influences both companies' stock performances following the announcement.
Read More: Sun Pharma (SUN) Acquires Organon for $11.75 Billion
Organon (OGN) Surges 39% on $12 Billion Merger Speculation
Organon & Co. (OGN) experienced a significant increase of 38.8% week-on-week following reports of a potential $12 billion acquisition by Sun Pharmaceutical Industries. No official confirmation has been issued regarding the merger. Additionally, Organon reported a decreased net income of 78% to $187 million in 2024, with revenues down 3% to $6.2 billion. In the fourth quarter, the company recorded a net loss of $205 million, compared to a net income of $109 million the previous year, while quarterly revenues also declined by 5.3% to $1.5 billion.
Read More: Organon (OGN) Surges 39% on $12 Billion Merger SpeculationMore Health Care stocks
Frequently asked questions
Is Organon & Co. in the S&P 500?
Yes. Organon & Co. trades as OGN and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is OGN in?
OGN sits in the Health Care sector of the S&P 500.
Where can I find the latest OGN news?
Right here. This page collects recent OGN news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Organon & Co.'s stock price?
OGN last traded at about $13.76. Prices move all through the session, so this is the latest quote rather than a live one.
What is Organon & Co.'s market cap?
OGN is worth roughly $3.61B. Market cap is the share price times the number of shares outstanding.
What is OGN's P/E ratio?
OGN trades at a trailing P/E ratio of about 17.6. The ratio compares the share price with earnings per share over the past year.